Michael Baim is appointed as Vice President - Bioanalytical Operations of the company effective May 7, 2018. Before joining BASi nearly four years ago, Dr. Bourdage enjoyed a long and esteemed career in the pharmaceutical industry. Having received his Ph.D. in immunochemistry from the University of Illinois, he served in leadership positions at Covance, PharmAthene, Eli Lilly, and Pharmacia/Upjohn. In addition to authoring numerous scientific papers, Dr. Bourdage is a member of the American Society of Clinical Pathologists and the American Association of Pharmaceutical Scientists. Dr. Michael Baim is an energetic and passionate leader who brings to BASi over thirty years of experience in the pharmaceutical and lab management industries. He is well-versed in analytical methodology and project design and has a proven track record of delivering significant and sustainable profitable growth across many different business segments. Dr. Baim received his B.A. degree in chemistry from Whitman College in Washington State. He then studied analytical chemistry as an American Chemical Society Analytical Research Fellow at Washington State University, where he earned his Ph.D. degree. He is currently working towards his MBA in marketing management. Dr. Baim began his career at The Procter & Gamble Company in 1984, and has since held several leadership, management and technical positions at other prominent companies including Novartis and Bristol-Myers Squibb/Mead Johnson. Most recently, he served as an analytical laboratory director, designing a new analytical chemistry lab and revitalizing chemistry operations by adding new technologies and staff to optimize technical guidance and improve customer service. These efforts resulted in a sustained, double-digit growth rate for the company.
Michael's mailing address filed with the SEC is C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE, IN, 47906-1382.
Over the last 21 years, insiders at Basis Global Technologies Inc have traded over $266,443 worth of Basis Global Technologies Inc stock and bought 540,162 units worth $1,698,287 . The most active insiders traders include Jacqueline M Lemke, Robert Jr. Leasure, and William D Pitchford. On average, Basis Global Technologies Inc executives and independent directors trade stock every 65 days with the average trade being worth of $128,544. The most recent stock trade was executed by Beth Taylor on 5 March 2021, trading 5,000 units of BASI stock currently worth $88,500.
Basis Global Technologies Inc executives and other stock owners filed with the SEC include: